Aerie Pharma (AERI) Gets a Buy Rating from Needham
Markets Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price target of $26.00. The company’s shares closed last Tuesday at $17.66. According to TipRanks.com, Belanger is a 4-star analyst with an average return of 8.8% and a 49.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical. Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $27.25, implying a 47.6% upside from current level...
Source: markets.co